PharmExec Picks:
Having trouble viewing this e-mail? Click here.
feed back

Update My Profile | Advertise With Us | Visit PharmExec.com |
PRINT SUBSCRIBE | DIGITAL SUBSCRIBE


Pharm Exec Picks is a biweekly eletter that delivers the most popular news and articles from the pharma space and highlights what's trending on social media.


Top 5 Stories :
Bridging Industry's Charisma Chasm
Pharma's image is still suffering despite a rise in medical innovation. Dan Bobear offers five patient-centered strategies that could help in finally mending the gap.
Read more
Hot and Cold: Biotech M&A and Financial Trends
Much of the criticism seems to be directed at the pharma companies, particularly around issues related to drug pricing, the seemingly endless stream of high profile take-overs, and the rush towards orphan drugs.
Read more

Do Sales Reps Hold the Key to Better Pharma Insights?
The role that emotion plays in the sales process is often underestimated. Whether a brand is preparing to launch a new product, or taking a reinvigorated one back to market, it is widely accepted that those who form the emotional connection with customers are most likely to succeed.
Read more
ASCO: Combos and Pricing and Pricing of Combos
Casey McDonald presents some highlights from a blustery few days in Chicago, with immunotherapy and cost, predictably taking center stage.
Read more
"There's a Cure for That..."
For the majority of us living today, that number is likely few, if any. While vaccines for polio, chicken pox and diphtheria made a dramatic 20th Century impact in life expectancy, until recently, cures and therapies with curative intent for serious diseases such as cancer and hepatitis C have been relatively unreliable and ineffective.
Read more
Trending on Social Media :
Blockbuster 2.0: Eight Ways to Follow that Leader
 Over the past decade, many industry journalists, analysts, and consultants presumed that specialty markets, pricing pressures, and pharmacogenetic testing would kill off billion-dollar products.
Read more
Top Five Pharma CEO Paypackets Total More Than $100M
Looking at aggregated data from The New York Times, which used filings from the Securities and Exchange Commission to compute CEO compensation, The Motley Fool, noting that four of the highest-paid CEOs in pharma saw their pay increase last year.
Read more
Manufacturers Continue to Fight Over Biosimilar Naming
 Probably the most contentious issue related to biosimilar development and marketing is whether follow-on therapies should have the same or different names from the reference drug.
Read more
Follow Us